Cataflam Shortage Update: What Patients Need to Know in 2026

Patients who take Cataflam (diclofenac potassium) for pain, arthritis, or menstrual cramps have faced real challenges at the pharmacy over the past several years. Here's an up-to-date look at the shortage history, the current status in 2026, and what you can do to make sure you get your medication.

Is Cataflam in Shortage Right Now (2026)?

As of 2026, there is no active national shortage of diclofenac potassium tablets listed by the FDA or the American Society of Health-System Pharmacists (ASHP). Multiple generic manufacturers — including Teva and Mylan/Viatris — currently supply the U.S. market.

However, it's important to understand that the original brand-name Cataflam — manufactured by Novartis — is no longer produced in the United States. When patients ask for "Cataflam" by brand name, some pharmacists may say it's unavailable or discontinued. The key is to ask specifically for generic diclofenac potassium 50 mg.

Shortage History: What Happened Between 2019 and 2020?

The most significant availability disruption for diclofenac potassium tablets occurred between early 2019 and mid-2020:

February 2019: ASHP added diclofenac potassium tablets to its drug shortage database

Sandoz: Permanently discontinued their diclofenac potassium product, reducing the number of available suppliers

Teva: Experienced a supply disruption without providing a public reason

August 2020: ASHP updated the shortage listing — all marketed products were available again through Mylan and Teva

The shortage was relatively brief but caused real disruption for patients who couldn't easily switch to another formulation, particularly those using it for dysmenorrhea where the fast-onset potassium salt is preferred.

Why Does Brand Discontinuation Affect Patients?

When a brand-name drug like Cataflam is discontinued, several problems arise for patients:

Prescriptions written for the brand name may confuse pharmacists who see it as discontinued in their system

Insurance systems may not recognize the brand for reimbursement, even when the generic is covered

Patients may not know to ask for the generic equivalent by its scientific name

Smaller pharmacies may have stopped stocking it due to low demand after the brand exit

How This Differs from a "Shortage" Drug

It's important to distinguish between Cataflam's situation and drugs that face ongoing supply crises. Cataflam is not in shortage in the traditional sense — the active pharmaceutical ingredient (diclofenac potassium) is manufactured and available. The difficulty patients face is primarily about:

Brand discontinuation creating confusion at the pharmacy level

Inconsistent stocking by individual pharmacies due to lower demand

Patients not knowing to ask for the generic by name

What Patients Should Do Right Now

If you take Cataflam and are having trouble filling your prescription, here are practical steps:

Ask for the generic: Tell your pharmacist you need "diclofenac potassium 50 mg immediate-release tablets" — not "Cataflam"

Use medfinder: medfinder calls pharmacies near you to find which ones have it in stock, then texts you the results

Plan ahead: Refill your prescription a week or two before running out so you have time to locate it

Talk to your doctor: If you consistently can't fill it locally, ask about switching to a more widely stocked NSAID such as meloxicam or naproxen

What to Watch for in 2026 and Beyond

As the generic market for diclofenac potassium consolidates around fewer manufacturers, there is always some risk of localized supply disruptions. The best strategy is to stay flexible — know your alternatives, refill early, and use tools like medfinder to locate stock quickly. For a provider-focused version of this update, see our prescriber shortage guide.